INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi ®, a biosimilar referencing Humira ® 1 (adalimumab), for the treatment of ...
Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...
Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback